🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great news for the DECIPHER #OesophagealCancer trial as the first patient has undergone treatment this week. This innovative #ClinicalTrial is testing if a targeted drug can improve outcomes and help stop the #cancer returning in certain patients. bit.ly/4cTFmLw

🆕 opportunity! 🧑‍⚕️Interested in novel IO & cell therapy in solid cancer? Keen to gain experience in early phase trials? Come join Fiona, me & our amazing team as a ‘Clinical Fellow in Advanced Immunotherapy & Cell Therapy Team’. Deadline 27 Nov 2024 👇 healthjobsuk.com/job/v6778827

👏 Great to see this published! VESTIGE is a negative randomised trial with an important lesson.. ➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo. 👀 Looking forward to the translational work annalsofoncology.org/article/S0923-…

Joining the #MedTwitter migration to #Medsky? Also at: bsky.app/profile/lizzys…

Feedback from the first 4 days on Bluesky 🦋: - <5 minutes to create an account - works exactly like Twitter (no need to re-learn anything) - much better feed, with high quality science and less toxic/political content - growing at impressive speed 👉Highly recommended Join us!

I have the empiric feeling that the Twitter algorithm may be hindering posts that include the name or links to 🦋 Guess that Elon may have read the news

What a great team effort! Thanks to The Lancet for this opportunity to write our #GastricCancer Seminar and a big 🙏🏻to all my colleagues for making it so easy!

📣 Updated ESMO #ClinicalPracticeGuideline on #localised #rectalcancer: tailored intensification/de-intensification, complex radiological factors, #biomarkers & organ-preserving Tx options. #ESMOGuidelines 🔗 ow.ly/q2VV50VWTAU

ESMO with a new Rectal Cancer CPG!

The OncoAlert 🚨 VJ Oncology JOURNAL CLUB This week Yelena Y. Janjigian MD from Memorial Sloan Kettering Cancer Center 🇺🇸 talks about her review article out on the Lancet on #GastricCancer thelancet.com/journals/lance… Gastric cancer causes nearly 1 million new cases and over 650,000 deaths annually, with rising

Huge news. New version of ESMO-MCBS is out! Introducing ESMO-MCBS v 2.0 with 13 new updates! Check it out today. Congratulations to the ESMO - Eur. Oncology -MCBS working group for the continued efforts to improve the tool and make it relevant and more valid. annalsofoncology.org/article/S0923-…

📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global ESMO - Eur. Oncology community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️

#ESMOMembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/XX3W50VZQyL FabriceAndre

#ASCO25 Checkmate 577 final OS ➡️ No significant OS benefit overall for adjuvant nivo SCC maybe....0.72 Adeno no .. HR 0.92 Post ESOPEC another reason to avoid CRT in adenocarcinoma 👀 MATTERHORN tomorrow folks!

#ASCO25 OG orals take homes: 1. CM577: adj nivo SCC only 🚫 mixed histology trials! 2. LEAP15: chemo+TKI+ICI=too much 🔎 Attention to the safety run-in 3. DG04: TDXD 1.1m PFS 3.3m OS ⬆️ 💉biopsy after 1L 4. CLD 18.2 CAR-T: 4m PFS 🔬 More work needed on tox vs efficacy

#ASCO25 Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity Exercise ➡️ marginal cost + negligible toxicity ✅ Evidence based intervention should be added to standard treatment recommendations No need to wait for regulatory approval! Do it now!

#ASCO25 Karin Jordin is my wonderful co-candidate in the #ESMO elections. We would both like to remind all ESMO - Eur. Oncology members to #vote! #friends #solidarity #education

The #OncoAlertTopTweet 🚨Day THREE of #ASCO25 Post by Lizzy Smyth MATTERHORN - first ever randomised trial to show a significant benefit for ICI (or any targeted therapy) in operable gastroesophageal cancer. ~10% ⬆️ EFS at 2y #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa